Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer

Anti-cancer Drugs
Hans-Georg StraussChristoph Thomssen

Abstract

Pegylated liposomal doxorubicin (PLD) is active in recurrent platinum-refractory ovarian and peritoneal cancer as demonstrated in a prospective-randomized trial. Dose-limiting toxicity in the US Food and Drug Administration-approved application schedule of PLD (50 mg/m2 every 4 weeks) was serious palmar-plantar erythrodysaesthesia (PPE). This phase II trial was aimed at reduction of the frequency of serious PPE without loss of efficacy by modifying both the application schedule and the total dose of PLD administered as palliative single-agent chemotherapy. Fifty patients were enrolled into this phase II trial. PLD was given via 30-min intravenous infusion at a dose of 20 mg/m2 every 2 weeks. Primary endpoint of the trial was the best response to chemotherapy. Secondary goals were progression-free survival, overall survival, and toxicity. Four complete responses and 16 partial responses were found resulting in an overall best response rate of 40.0%. The median progression-free survival in the intention-to-treat-population was 4.1 months [95% confidence interval (CI), 2.8-5.4 months], whereas the overall survival was 16.5 months (95% CI, 12.3-20.7 months). Although 17 (34.0%) patients developed some PPE, only one progressed to gr...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G RoseH D Homesley
Sep 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G BerryF J Martin
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurie MarkmanMark Baker
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacobus PfistererUNKNOWN EORTC GCG

❮ Previous
Next ❯

Citations

Oct 31, 2003·Critical Reviews in Oncology/hematology·Erika FruscellaGiovanni Scambia
Mar 26, 2011·Expert Opinion on Drug Metabolism & Toxicology·Matteo MorottiSimone Ferrero
Sep 8, 2010·Expert Opinion on Investigational Drugs·Koji MatsuoAnil K Sood
Jul 16, 2011·AIChE Journal·Shy Chyi WuangDaniel W Pack
May 21, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Annette DegenRalf Gutzmer
May 26, 2016·American Journal of Clinical Dermatology·Kumutnart ChanprapaphVasanop Vachiramon
Aug 2, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Karina Dahl SteffensenAnders Jakobsen
Dec 6, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Karina Dahl SteffensenAnders Jakobsen
Aug 5, 2011·Drugs·R Wendel Naumann, Robert L Coleman
Jun 28, 2020·European Journal of Hospital Pharmacy. Science and Practice·Yao ZhuXiaoling Zheng

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.